

Table 3. Detailed demographic characteristics of the Harvard Brain Tissue Resource Center Study Group

Nonpsychiatric subjects											
a	b	c	d	e	f	g	h	i	j	k	l
M	66	19	6.8	1.1	1.4	1.5	44	-	1	-	-
M	40	28	6.5	1.7	3.4	0.5	46	-	3	-	-
M	69	15	6.9	1.3	2.8	1.5	44	-	1	-	-
F	78	14	6.2	1.6	2.5	1.3	42	-	1	-	-
M	36	24	6.3	1.5	2.3	1.1	44	-	1	-	-
M	37	19	6.7	1.2	1.4	1.3	49	-	3	-	-
M	49	25	6.8	1.0	1.5	1.4	45	-	1	-	-
M	29	18	7.1	1.2	1.8	1.3	44	-	5	-	-
F	53	24	5.8	2.3	3.6	0.6	44	-	2	-	-
M	40	17	6.2	1.2	2.0	1.2	48	-	1	-	-
F	74	12	6.3	1.5	2.3	0.8	45	-	5	-	-
M	54	24	6.6	1.0	1.5	1.3	53	-	1	-	-
M	36	20	6.0	1.6	2.3	0.9	48	-	1	-	-
F	70	22	6.3	2.3	3.7	0.4	37	-	2	-	-
M	67	22	6.4	1.1	1.7	1.4	48	-	1	-	-
M	42	18	6.8	1.0	1.4	1.1	54	-	1	-	-
M	79	21	6.7	1.5	2.8	0.6	49	-	2	-	-
F	78	24	6.7	1.4	2.3	0.9	48	-	2	-	-
M	38	29	6.5	1.1	1.5	1.5	49	-	1	-	-
F	65	24	6.4	1.1	1.8	1.3	52	-	5	-	-
F	66	7	6.0	1.5	2.5	0.6	47	-	2	-	-
M	89	7	6.4	1.5	2.4	1	47	-	2	-	-
M	35	26	6.3	1.2	1.4	1.4	40	-	5	-	-
M	50	24	6.0	2.1	3.1	1.1	42	-	5	-	-
M	84	29	6.4	2.2	5.0	0.5	44	-	1	-	-
M	73	20	6.0	1.5	2.5	1	40	-	5	-	-

Schizophrenia patients											
a	b	c	d	e	f	g	h	i	j	k	l
M	66	22	6.4	1.0	1.4	1.8	48	20	1	H	Y
F	83	23	5.9	2.0	3.5	0.2	42	55	3	H	Y
M	44	19	6.0	3.0	4.0	0.9	34	20	1	Cz	N
M	35	28	6.2	1.6	2.1	1	46	31	1	UN	N
M	46	18	6.3	3.2	2.6	1	45	19	3	V, O	Y
M	26	16	6.7	1.3	2.6	1.6	50	23	4	F	Y
M	42	27	6.6	1.0	2.0	1.2	45	16	2	NT	Y
M	47	19	6.6	2.0	4.0	1.9	47	17	2	NT	N
M	31	15	6.5	1.2	2.0	1.1	49	19	5	R, O, Bp	Y
M	80	11	6.4	1.4	1.8	0.5	41	17	1	Th, Mr	N
M	49	19	6.6	1.0	1.2	1.8	50	19	4	H	Y

M	61	20	6.7	1.5	2.2	1.5	46	25	3	H	N
F	73	24	6.1	1.6	3.0	0.5	47	23	2	R, Fx	N
M	63	22	6.5	1.1	2.8	1.3	50	7	1	Cz, Ta, H	N
F	72	22	6.6	1.2	2.0	0.7	50	24	2	R, Pa	N
F	84	26	6.1	1.7	2.8	0.5	40	34	1	V	N
M	42	18	6.3	1.3	2.1	1	46	27	4	Ta	Y
F	78	13	6.8	1.5	2.3	1.2	46	16	3	L, H	N
F	48	34	6.6	1.2	1.5	1.3	47	17	1	V, R Y	

Bipolar patients with psychosis

a	b	c	d	e	f	g	h	i	j	k	l
F	64	11	6.7	1.0	1.7	1.3	51	20	1	V, Cr, T, D	N
M	38	41	6.5	1.0	1.2	1.4	43	37	4	Se, L, V	N
F	80	12	6.5	3.0	4	1	27	38	3	Pe, V	N
F	42	16	6.3	1.1	1.7	1.3	52	20	4	V, L, Pe	Y
M	78	30	6.3	1.9	4.2	0.7	42	49	1	Ch, F, V, L	N
F	76	23	6.6	1.9	3.8	0.5	42	67	1	L	Y
M	74	25	6.5	1.4	3.4	0.8	47	50	1	V, Q	Y
M	74	7	6.7	2.9	4.1	1.3	33	72	1	O	N
F	55	18	6.5	-	-	0.7	47	40	2	V	Y
F	73	21	6.3	1	1.6	1.2	51	25	3	R	N
M	74	14	6.3	1.9	2.7	0.5	38	18	1	O, L, V	N
F	73	17	6.4	2.0	3.5	0.5	42	25	3	V, R, Se	N
M	40	31	6.0	1.3	2.4	0.6	48	25	4	R, Nf, Z	Y
M	83	17	6.6	1.6	3	1.3	47	43	1	V, Pa	Y

Bipolar patients without psychosis

a	b	c	d	e	f	g	h	i	j	k	l
M	51	31	7.0	1.8	3.4	0.9	44	-	5	UK	-
F	29	11	6.7	1.1	1.6	1.3	45	-	4	V, L, P, O	Y
M	50	30	6.3	1.6	4.2	1.0	47	34	1	L	Y
M	82	5	6.4	1.4	1.8	1.2	49	40	1	NT	Y
M	38	22	6.2	1.4	2.1	1.3	43	25	4	V, Pa, O	N

a, gender; **b**, age (yr); **c**, postmortem interval (PMI) (interval between death and brain fixation in formaldehyde in h); **d**, brain pH; **e**, 3'/5' glyceraldehyde-3-phosphate dehydrogenase (G3PDH) ratio; **f**, 3'/5' β -actin ratio; **g**, 28s/18s RNA ratio; **h**, percent probe sets present; **i**, age of onset of illness in yr; **j**, cause of death (1, cardiopulmonary failure; 2, cancer; 3, other; 4, suicide; 5, unknown); **k**, medication (Bp, bupropion; Cr, carbamazepine; Ch, chlorpromazine; Cz, clozapine; D, doxepin; Fx, fluoxetine; F, fluphenazine; H, haloperidol; L, lithium; Mr, mirtazapine; Nf, nefazodone; O, olanzapine; Q, quetiapine; Pa, paroxetine; Pe, perphenazine; P, phenelzine; R, risperidone; Se, sertraline; Th, thioridazine; Ta, trazodone; T, trifluoperazine; V, valproic acid; Z, ziprasidone; UN, never treated; NT, not treated 6 months or more before death; UK, unknown); **l**, abuse or dependency history (Y, yes; N, no).